Examining ADAURA and the Advantages of Adjuvant Osimertinib in EGFR+ NSCLC
Season 3, Episode 23, Jul 23, 2020, 08:27 PM
In our exclusive interview, Dr. Aggarwal, Dr. Sequist, and Dr. Pennell provided perspective on the results of the ADAURA trial and addressed the potential clinical and financial concerns of using osimertinib in the adjuvant setting in patients with EGFR-mutant non–small cell lung cancer.